Category
Tafamidis
CAS Number
1507158-86-2
Molecular Formula
C₁₄H₇Cl₂NO₃
Molecular Weight
308.11 g/mol
Synonym

2-(3,4-dichlorphenyl)-6-benzoxazolecarboxylic acid; 6-Benzoxazolecarboxylic acid, 2-(3,4-dichlorophenyl)-; 2-(3,4-dichlorophenyl)benzo[d]oxazole-6-carboxylic Acid; 6-Benzoxazolecarboxylic acid,2-(3,4-dichlorophenyl)

Keywords
Pharmaceutical Standards
Metabolites.
Impurities
slide.1
Purity:

Above - 95.0%

Technical Data:

We will provide complete documentation support for every Standard Material. All analytical reports such as ¹H NMR, ¹³C NMR, Mass, FT-IR, HPLC Purity/GC Purity/QNMR Purity, Water content by KF/ Loss on Drying/TGA (Thermo-gravimetric Analysis). Certificate of Analysis with potency report. Each Standard Material SER (Structure Elucidation Report) with NMR, Mass, IR spectral interpretation. This whole analytical document can be included in eCTD, ANDA, DMF submissions to regulatory agencies.

Tafamidis Impurity 4 is a process-related impurity associated with the synthesis or degradation of the drug Tafamidis, used in the treatment of transthyretin amyloidosis. It is typically formed as a minor by-product during manufacturing or through degradation pathways under certain storage or stress conditions. This impurity is monitored and controlled through validated analytical techniques such as HPLC or LC–MS to ensure the purity, safety, and regulatory compliance of the final drug substance.